Business
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
– Adds to comprehensive patent portfolio underlying novel ThermoStem® technology platform – – Expanding intellectual property estate expected to help drive
About this update from Biorestorative Therapies, Inc.
[{"type":"text","content":"– Adds to comprehensive patent portfolio underlying novel ThermoStem® technology platform – – Expanding intellectual property estate expected to help drive ThermoStem® licensing opportunities – – Substantive discussions continue with commercial stage regenerative medicine company with regard to a license of ThermoStem® IP – MELVILLE, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, is pleased to announce that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-564135 related to the Company’s allogeneic, off-the-shelf ThermoStem® platform. Previously published peer-reviewed preclinical data from a study conducted in collaboration with the University of Utah School of Medicine (“UUSOM”) demonstrated a clonogenic population of metabolically active brown adipose tissue (“BAT”) stem cells residing in adult humans that: (i) can be expanded in vitro; (ii) exhibit multilineage differentiation potential (osteogenetic, chondrogenic and adipogenic); and (iii), functionally differentiate into metabolically active brown adipocytes. In addition, the preclinical results confirmed that multipotent brown adipose derived stem cells (“BADSCs”) induced to differentiate into brown adipocytes exhibit the mature functional properties of these cells, including increased mitochondrial activity, an important functional characteristic of BAT. In the UUSOM study, data obtained in high-fat fed NOD-SCID mice transplanted with differentiated BADSCs supported by a BioRestorative-developed 3D Porous Extracellular Matrix-Derived Scaffold showed significant reductions in weight (consistent with losses achieved by GLP1 drugs), triglyceride and blood glucose levels compared to saline-only injected controls. The study also demonstrated that BioRestorative’s 3D scaffold was capable of retaining viable transplanted cells for at least five weeks post-implantation. This, the fifth Japanese patent to issue for BioRestorative’s ThermoStem® technology platform, covers a method of making three-dimensional brown adipose derived stem cell aggregates in the absence of differentiation medium. “As awareness of the promise that our ThermoStem®-based BADSCs hold for the treatment of obesity...